Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Opening Session Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Deborah Collyar: What's In It for Patients?

Welcome and Introduction to Vi3C

Jul

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Opening Session Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Deborah Collyar: What's In It for Patients?

Welcome and Introduction to Vi3C

Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes

Long-Term Outcomes With SABR in Primary Kidney Cancer

Long-Term Follow-up of Postoperative Chemoradiotherapy With Weekly vs Every-3-Week Cisplatin in Head and Neck Cancer

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Mutant KRAS Vaccine for Prevention of Pancreatic Cancer Development Shows Durable Immune Responses